Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 8/20 | 0.42 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | ALPI | P09923 | 1/20 | 0.36 |
| ▸ | ALPG | P10696 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14770504 | 0.88 | BRD4 (0.42) | AMY1ABRD4ALPLALPIALPG | |
| SCHEMBL14770490 | 0.87 | AMY1A (0.43) | AMY1AHPSEBRD4ALPLALPI | |
| SCHEMBL14770652 | 0.87 | MEN1 (0.37) | AMY1AHPSEL3MBTL1TP53MAPT | |
| SCHEMBL14770682 | 0.86 | AMY1A (0.41) | AMY1ABRD4ALPLALPIALPG | |
| SCHEMBL14770650 | 0.84 | AMY1A (0.50) | AMY1AHPSEL3MBTL1TP53MAPT | |
| SCHEMBL14770733 | 0.82 | IDO1 (0.42) | AMY1ABRD4HTR2C | |
| SCHEMBL14770655 | 0.82 | MEN1 (0.46) | HPSETP53MAPTTSHR | |
| SCHEMBL14770492 | 0.82 | AMY1A (0.41) | AMY1AALPLALPIALPGMAPT | |
| SCHEMBL14770501 | 0.77 | MLKL (0.46) | BRD4ALPLALPIALPGTP53 | |
| SCHEMBL12065630 | 0.77 | MLKL (0.41) | AMY1AHPSEBRD4ALPLALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | AMY1A 4661/4885HPSE 4805/4885BRD4 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.